Anthera Pharmaceuticals (ANTH) vs. Its Peers Head to Head Comparison
Anthera Pharmaceuticals (NASDAQ: ANTH) is one of 288 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Anthera Pharmaceuticals to related companies based on the strength of its valuation, institutional ownership, earnings, risk, dividends, profitability and analyst recommendations.
Valuation and Earnings
This table compares Anthera Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Anthera Pharmaceuticals||N/A||-$50.12 million||-0.14|
|Anthera Pharmaceuticals Competitors||$473.35 million||$171.87 million||-6.87|
Anthera Pharmaceuticals’ competitors have higher revenue and earnings than Anthera Pharmaceuticals. Anthera Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
27.3% of Anthera Pharmaceuticals shares are held by institutional investors. Comparatively, 51.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.6% of Anthera Pharmaceuticals shares are held by insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility & Risk
Anthera Pharmaceuticals has a beta of 2.68, suggesting that its share price is 168% more volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals’ competitors have a beta of 6.57, suggesting that their average share price is 557% more volatile than the S&P 500.
This table compares Anthera Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anthera Pharmaceuticals Competitors||-4,921.75%||-357.18%||-43.57%|
This is a summary of current recommendations for Anthera Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anthera Pharmaceuticals Competitors||1389||4503||12346||313||2.62|
Anthera Pharmaceuticals currently has a consensus price target of $5.89, indicating a potential upside of 320.54%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.24%. Given Anthera Pharmaceuticals’ higher possible upside, research analysts clearly believe Anthera Pharmaceuticals is more favorable than its competitors.
Anthera Pharmaceuticals competitors beat Anthera Pharmaceuticals on 10 of the 12 factors compared.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.